Efficacy and safety of bone management agents administered at 12 weeks vs. 4 weeks in patients with bone metastases: A systematic review.

Junya Sato,Makoto Kodaira,Hiroyuki Harada,Haruo Iguchi,Taichi Yoshida,Hiroyuki Shibata

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners（2023）

引用 0|浏览1

暂无评分

摘要

This meta-analysis showed no influence of BMA de-escalation on the incidence of SRE; nevertheless, AEs appeared to reduce with the de-escalated usage of ZA.

查看译文

关键词

Bone modifying agents,adverse event,bisphosphonate,de-escalation,skeletal-related event

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要